All In Biotech

Drug Trial Radar · NCT05027373

Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection

A Randomized, Double-blind, Placebo-controlled Parallel Trial of Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody by Single Subcutaneous Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

34

Planned (sponsor's estimate)

Start

Aug 13, 2021

Primary completion

Apr 30, 2022

Study completion Sep 30, 2022

Sponsor

Sponsor type
Industry
First posted
Aug 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects. Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated.

Conditions

  • Systemic Juvenile Idiopathic Arthritis
  • Periodic Fever Syndrome

Interventions

  • SSGJ-613Drug

    SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.

  • PlaceboDrug

    Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: up to 112 days
  2. TmaxTime frame: up to 112 days
  3. AUC0-tTime frame: up to 112 days
  4. t1/2Time frame: up to 112 days
  5. CL/FTime frame: up to 112 days
  6. Vd/FTime frame: up to 112 days
  7. KeTime frame: up to 112 days
  8. AUC0-∞Time frame: up to 112 days
  9. AETime frame: up to 112 days
  10. SAETime frame: up to 112 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui District Central Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.